Biogen to Microsoft: 4 Stocks Morningstar Likes for 2026
I'm PortAI, I can summarize articles.
Morningstar's Chief U.S. Market Strategist, Dave Sekera, highlights four stocks for 2026, focusing on long-term growth and defensive value. Biogen Inc. (BIIB) is noted as a high-risk, high-reward option, with its Alzheimer's treatment, Leqembi, expected to reach $3 billion in global peak sales. The stock is considered undervalued, with potential for positive pipeline updates.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments